Evidence map›Paper›PMID 30002479›Full record

ReviewNature reviews. Cancer2018

Every step of the way: integrins in cancer progression and metastasis.

Hellyeh Hamidi, Johanna Ivaska

Erratum issuedAbstract readReview
In one paragraph

Review in Nature reviews. Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 882 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
882citing papers in PubMed, 1 pooled it
83.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

882 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,463 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Understanding and targeting the tumour matrisome.Nature reviews. Clinical oncology · 2026
    Review
  6. Review
  7. Review
  8. Article
  9. FASEB bioAdvances · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

822 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hellyeh HamidiTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
Johanna IvaskaTurku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland. johanna.ivaska@utu.fi.ORCID http://orcid.org/0000-0002-6295-6556
Åbo Akademi University · FI

Funding

European Research Council 615258
6 · The paper itself

Abstract

Cell adhesion to the extracellular matrix is fundamental to tissue integrity and human health. Integrins are the main cellular adhesion receptors that through multifaceted roles as signalling molecules, mechanotransducers and key components of the cell migration machinery are implicated in nearly every step of cancer progression from primary tumour development to metastasis. Altered integrin expression is frequently detected in tumours, where integrins have roles in supporting oncogenic growth factor receptor (GFR) signalling and GFR-dependent cancer cell migration and invasion. In addition, integrins determine colonization of metastatic sites and facilitate anchorage-independent survival of circulating tumour cells. Investigations describing integrin engagement with a growing number of versatile cell surface molecules, including channels, receptors and secreted proteins, continue to lead to the identification of novel tumour-promoting pathways. Integrin-mediated sensing, stiffening and remodelling of the tumour stroma are key steps in cancer progression supporting invasion, acquisition of cancer stem cell characteristics and drug resistance. Given the complexity of integrins and their adaptable and sometimes antagonistic roles in cancer cells and the tumour microenvironment, therapeutic targeting of these receptors has been a challenge. However, novel approaches to target integrins and antagonism of specific integrin subunits in stringently stratified patient cohorts are emerging as potential ways forward.

Indexed as

Cell AdhesionCell MovementNeoplasm InvasivenessNeoplasm MetastasisDisease ProgressionHumansIntegrinsNeoplasmsNeoplastic Cells, CirculatingReceptors, Growth FactorSignal TransductionTumor MicroenvironmentIntegrinsReceptors, Growth Factor

Identifiers

PMID30002479
PMCPMC6629548
OpenAlexW2867022353

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.